

**§ 510.600 [Amended]**

■ 2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for "Anthony Products Co." and in the table in paragraph (c)(2) by removing the entry for "000864".

**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**

■ 3. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 520.1720a [Amended]**

■ 4. Section 520.1720a *Phenylbutazone tablets and boluses* is amended in paragraph (b)(3) by removing "000864".

**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**

■ 5. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 522.480 [Amended]**

■ 6. Section 522.480 *Repository corticotropin injection* is amended in paragraph (b)(2) by removing "000864" and by adding in its place "061623".

**§ 522.540 [Amended]**

■ 7. Section 522.540 *Dexamethasone injection* is amended in paragraphs (b)(2)(i) and (c)(2) by removing "000864" and by adding in its place "061623".

**§ 522.1010 [Amended]**

■ 8. Section 522.1010 *Furosemide* is amended in paragraph (b)(2) by removing "000864" and by adding in its place "061623".

**§ 522.1720 [Amended]**

■ 9. Section 522.1720 *Phenylbutazone injection* is amended in paragraph (b)(1) by removing "and 059130" and by adding in its place "059130, and 061623"; in paragraph (b)(2) by removing "Nos. 000010 and 000864" and by adding in its place "No. 000010"; and by removing paragraph (b)(4).

■ 10. Section 522.1883 is revised to read as follows:

**§ 522.1883 Prednisolone sodium phosphate.**

(a) *Specifications.* Each milliliter of solution contains 20 milligrams (mg) prednisolone sodium phosphate (equivalent to 14.88 mg of prednisolone).

(b) *Sponsor.* See No. 061623 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs—(1) Amount.* Administer intravenously in a dosage of 2 1/2 to 5 mg per pound of body weight, initially for shock and shock-like states, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal.

(2) *Indications for use.* Administer when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

■ 11. Section 522.1962 is amended:

■ a. By removing "injection" from the heading;

■ b. By removing footnote 1;

■ c. In paragraph (b) by removing "000864" and by adding in its place "061623";

■ d. By removing paragraphs (c)(3) and (c)(4);

■ e. By revising paragraphs (a) and (c)(2); and

■ f. By adding a heading to (c)(1).

■ The amendments read as follows:

**§ 522.1962 Promazine hydrochloride.**

(a) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) promazine hydrochloride.

\* \* \* \* \*

(c) \* \* \*

(1) *Amounts and indications for use.*

(i) \* \* \*

\* \* \* \* \*

(2) *Limitations.* Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**§ 522.2063 [Amended]**

■ 12. Section 522.2063 *Pyriminylamine maleate injection* is amended in paragraph (b) by removing "000864" and by adding in its place "061623".

**PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS**

■ 13. The authority citation for 21 CFR part 529 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 529.1044a [Amended]**

■ 14. Section 529.1044a *Gentamicin sulfate intrauterine solution* is amended in paragraph (b) by removing "000864, 057561, and 059130" and by adding in its place "057561, 059130, and 061623".

Dated: October 2, 2003.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 03-26336 Filed 10-17-03; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF COMMERCE****Patent and Trademark Office****37 CFR Part 1**

[Docket No. 2003-P-021]

RIN 0651-AB61

**January 2004 Revision of Patent Cooperation Treaty Application Procedure**

**AGENCY:** Patent and Trademark Office, Commerce.

**ACTION:** Final rule.

**SUMMARY:** The United States Patent and Trademark Office (Office) is amending the rules of practice to conform them to certain amendments made to the Regulations under the Patent Cooperation Treaty (PCT) that will take effect on January 1, 2004. These amendments will result in the addition of a written opinion in PCT Chapter I, as well as a simplification of PCT designations and the PCT fee structure. In addition, the Office is adjusting the transmittal, search, and international preliminary examination fees for international applications filed under the PCT to be more closely aligned with the actual average costs of processing a PCT application and conducting a PCT search and international preliminary examination under the new process.

**EFFECTIVE DATE:** January 1, 2004.

**FOR FURTHER INFORMATION CONTACT:**

Richard R. Cole, Legal Examiner, Office of PCT Legal Administration (OPCTLA) directly by telephone at (703) 305-6639, or by facsimile at (703) 308-6459.

**SUPPLEMENTARY INFORMATION:** During the September-October 2002 meeting of the Governing Bodies of the World Intellectual Property Organization (WIPO), the PCT Assembly adopted various amendments to the Regulations under the PCT that enter into force on January 1, 2004. The amended PCT Regulations were published in the PCT Gazette of December 5, 2002 (49/2002), in Section IV, at pages 25004-61. The purposes of these amendments are to:

(1) Improve coordination of international search (Chapter I of the PCT) and international preliminary examination (Chapter II of the PCT) through the provision of an enhanced international search and preliminary examination system; (2) simplify the PCT by changing the concept and operation of the designation system and the fee system; and (3) simplify signature and other filing requirements.

*Enhanced International Search and Preliminary Examination System:* Under the enhanced international search and